Pulmonary Hypertension

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors — WHO Classification
  5. Clinical Presentation — WHO Functional Class
  6. Diagnosis
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research and Advances
  12. References

1. Overview

Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined as a mean pulmonary arterial pressure (mPAP) >20 mmHg at rest, measured by right heart catheterization. It is a common endpoint of diverse diseases affecting the pulmonary vasculature, cardiac chambers, lung parenchyma, or ventilatory control. Left untreated, progressive pulmonary vascular resistance leads to right ventricular failure and death. Pulmonary arterial hypertension (PAH), the most extensively studied subgroup, is defined additionally by a pulmonary arterial wedge pressure ≤15 mmHg and pulmonary vascular resistance (PVR) >2 Wood units (WU), indicating a pre-capillary etiology. The 2022 ESC/ERS guidelines updated the mPAP threshold from 25 to 20 mmHg, recognizing that even mildly elevated pressures confer increased morbidity and mortality.

2. Epidemiology

PH affects an estimated 1% of the global population, rising to 10% among those over 65 years of age, primarily driven by left heart disease and lung disease (WHO Groups 2 and 3). Idiopathic PAH (IPAH), the most studied form, has an estimated incidence of 2–5 cases per million per year and a prevalence of 15–50 per million. Women are disproportionately affected by PAH at a ratio of approximately 2–4:1 over men, though males tend to have worse RV adaptation and prognosis at diagnosis.

Connective tissue disease-associated PAH (CTD-PAH), particularly systemic sclerosis (SSc), is one of the most prevalent forms of Group 1 PAH, affecting 8–12% of SSc patients and carrying a 3-year mortality of ~50%. Heritable PAH (HPAH) accounts for ~15–20% of apparently idiopathic cases, with BMPR2 mutations identified in ~80% of HPAH and ~20% of IPAH patients. The French National Registry documented a median survival from diagnosis of 2.8 years before the modern treatment era, substantially improved with contemporary targeted therapies.

3. Pathophysiology

The pathobiology of PAH involves a complex interplay of vasoconstriction, vascular remodeling, inflammation, and thrombosis in situ. Three principal pathways are dysregulated:

  1. Nitric oxide (NO) pathway: Reduced endothelial NO synthase (eNOS) activity and decreased NO bioavailability impair vasorelaxation. Phosphodiesterase type 5 (PDE5) degrades cyclic GMP (cGMP); PDE5 inhibitors restore this pathway.
  2. Prostacyclin pathway: Decreased prostacyclin synthase expression reduces PGI2 production, tipping the balance toward vasoconstriction and platelet aggregation (excess thromboxane A2).
  3. Endothelin-1 (ET-1) pathway: ET-1 is markedly upregulated, acting on ETA receptors (vasoconstriction, smooth muscle proliferation) and ETB receptors (vasodilation, clearance). Endothelin receptor antagonists target this pathway.

Histologically, PAH is characterized by plexiform lesions — disordered angioproliferative lesions arising from monoclonal expansion of endothelial cells, medial hypertrophy (smooth muscle cell proliferation), intimal fibrosis, adventitial thickening, and in situ thrombosis. The net effect is progressive elevation of PVR.

The right ventricle adapts initially via concentric hypertrophy (adaptive remodeling), maintaining cardiac output. As PVR continues to rise, the RV dilates (maladaptive remodeling), tricuspid regurgitation develops, interventricular septal deviation compresses the LV, and cardiac output falls — the final common pathway of right heart failure.

In Group 2 PH (left heart disease), elevated left atrial pressure is transmitted retrogradely; initially passive (postcapillary PH), it may trigger reactive pulmonary vasoconstriction and remodeling (combined pre- and postcapillary PH, CpcPH).

4. Etiology and Risk Factors — WHO Classification

The updated WHO Clinical Classification (Nice 2018/ESC 2022) organizes PH into five groups:

Group 1 — Pulmonary Arterial Hypertension (PAH)

Group 2 — PH Due to Left Heart Disease

Group 3 — PH Due to Lung Disease and/or Hypoxia

Group 4 — Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Group 5 — PH with Unclear or Multifactorial Mechanisms

5. Clinical Presentation — WHO Functional Class

Symptoms develop insidiously; the diagnosis is often delayed by 2–3 years. Early PH is clinically silent or mimics more common conditions.

Symptoms:

Signs:

The WHO Functional Classification (modified from NYHA) stratifies symptom burden:

6. Diagnosis

Diagnosis requires a systematic evaluation to confirm PH, characterize severity, and classify etiology.

Non-invasive Evaluation

Right Heart Catheterization (RHC)

The gold standard for definitive diagnosis. Mandatory before initiating PAH-specific therapy. Measures:

Vasoreactivity testing: Performed during RHC using inhaled NO (40 ppm), IV adenosine, or inhaled iloprost. A positive response (mPAP decrease ≥10 mmHg to absolute value ≤40 mmHg, with maintained or increased CO) identifies approximately 10% of IPAH patients eligible for calcium channel blocker therapy.

7. Treatment

Management is stratified by WHO group and risk category. PAH-specific vasodilator therapy is used only in Group 1 (and CTEPH with residual disease). Groups 2 and 3 require treatment of the underlying condition; PAH therapies may be harmful in Group 2.

General Measures

Calcium Channel Blockers (CCBs)

Reserved for vasoreactive-positive IPAH patients (∼10%). Nifedipine, diltiazem, or amlodipine at high doses. Annual reassessment of sustained response required.

Targeted PAH Therapies — Three Approved Pathways

Endothelin Receptor Antagonists (ERAs)

PDE5 Inhibitors and sGC Stimulators

Prostacyclin Pathway Agents

Combination Therapy

Initial combination therapy with ERA + PDE5i is now preferred over sequential add-on therapy for most treatment-naive Group 1 PH patients based on the AMBITION trial (ambrisentan + tadalafil vs. monotherapy). Triple combination therapy (ERA + PDE5i + prostacyclin pathway agent) is used for high-risk or deteriorating patients.

CTEPH-Specific Treatment

Lung Transplantation

Reserved for WHO FC III–IV patients failing maximal medical therapy. Bilateral lung transplant preferred. Median survival post-transplant ~5–6 years.

8. Complications

9. Prognosis

Prognosis varies markedly by WHO group and individual patient factors. For PAH, the REVEAL 2.0 risk calculator and ESC/ERS low-/intermediate-/high-risk stratification guide treatment escalation:

With modern combination therapy, 5-year survival for IPAH has improved from ~34% in the pre-treatment era to >60–70%. SSc-PAH continues to carry a worse prognosis (~50% 3-year mortality) due to underlying disease complexity. CTEPH treated with PEA has 5-year survival exceeding 80%.

10. Prevention

11. Recent Research and Advances

Sotatercept (ACE-011): An activin signaling inhibitor that rebalances the BMPR2/activin receptor signaling axis — the fundamental molecular defect in PAH. The PULSAR and STELLAR trials demonstrated significant reductions in PVR, improvements in 6MWD, and reductions in NT-proBNP. FDA approved in 2024 for WHO Group 1 PAH; represents the first approved therapy targeting the underlying vascular remodeling process rather than just vasoconstriction.

Ralinepag and Other IP Receptor Agonists: Next-generation prostacyclin receptor agonists with longer half-lives and improved tolerability are in late-stage development.

TYVASO DPI (inhaled treprostinil dry powder): FDA approved for PAH and PH-ILD (Group 3); the INCREASE trial demonstrated improvement in 6MWD and reduction in clinical worsening in PH-ILD — the first approval for Group 3 PH.

Genetic and Molecular Advances: Next-generation sequencing has identified novel causal genes beyond BMPR2 (GDF2/BMP9, ATP13A3, AQP1, SOX17), broadening understanding of the genetic architecture of PAH. iPSC-derived models from BMPR2-mutant patients are advancing drug discovery.

HFpEF-PH Phenotyping: Recognizing Group 2 PH in HFpEF requires hemodynamic exercise testing; passive vs. reactive PH subtypes have different prognoses and treatment implications. Trials of ERA and PDE5i in HFpEF-PH have yielded negative or mixed results, reinforcing the importance of correct group classification.

12. References

  1. Humbert M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi:10.1093/eurheartj/ehac237
  2. Simonneau G, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41. doi:10.1016/j.jacc.2013.10.029
  3. Tuder RM, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D4–12. doi:10.1016/j.jacc.2013.10.025
  4. Galiè N, et al. (AMBITION Investigators). Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834–844. doi:10.1056/NEJMoa1413687
  5. Pulido T, et al. (SERAPHIN Investigators). Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818. doi:10.1056/NEJMoa1213917
  6. Sitbon O, et al. (GRIPHON Investigators). Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533. doi:10.1056/NEJMoa1503184
  7. Ghofrani HA, et al. (PATENT-1). Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–340. doi:10.1056/NEJMoa1209655
  8. Ghofrani HA, et al. (CHEST-1). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–329. doi:10.1056/NEJMoa1209657
  9. Hoeper MM, et al. A global view of pulmonary arterial hypertension. Lancet Respir Med. 2016;4(4):306–322. doi:10.1016/S2213-2600(15)00543-3
  10. Badesch DB, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S55–66. doi:10.1016/j.jacc.2009.04.011
  11. Rosenzweig EB, et al. Sotatercept for the treatment of pulmonary arterial hypertension (STELLAR). N Engl J Med. 2023;388(16):1478–1490. doi:10.1056/NEJMoa2213558
  12. Channick RN, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–1123. doi:10.1016/S0140-6736(01)06250-X
  13. Barberà JA, et al. Pulmonary hypertension in COPD. Eur Respir J. 2003;21(5):892–905. doi:10.1183/09031936.03.00115402
  14. Olsson KM, et al. REVEAL 2.0: Updated risk score for pulmonary arterial hypertension. Chest. 2019;156(2):323–337. doi:10.1016/j.chest.2019.02.004
  15. Waxman A, et al. (INCREASE Trial). Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–334. doi:10.1056/NEJMoa2008470
  16. Delcroix M, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension. Circulation. 2016;133(9):859–871. doi:10.1161/CIRCULATIONAHA.115.016522

Back to Table of Contents